Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.

MLA

Attwood, Marie, et al. “Antibacterial Effect of Seven Days Exposure to Ceftolozane-Tazobactam as Monotherapy and in Combination with Fosfomycin or Tobramycin against Pseudomonas Aeruginosa with Ceftolozane-Tazobactam MICs at or above 4 Mg/l in an in Vitro Pharmacokinetic Model.” Journal of Antimicrobial Chemotherapy (JAC), vol. 78, no. 9, Sept. 2023, pp. 2254–62. EBSCOhost, https://doi.org/10.1093/jac/dkad230.

APA

Attwood, M., Griffin, P., Noel, A. R., Albur, M., & Macgowan, A. P. (2023). Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model. Journal of Antimicrobial Chemotherapy (JAC), 78(9), 2254–2262. https://doi.org/10.1093/jac/dkad230

Chicago

Attwood, Marie, Pippa Griffin, Alan R Noel, Maha Albur, and Alasdair P Macgowan. 2023. “Antibacterial Effect of Seven Days Exposure to Ceftolozane-Tazobactam as Monotherapy and in Combination with Fosfomycin or Tobramycin against Pseudomonas Aeruginosa with Ceftolozane-Tazobactam MICs at or above 4 Mg/l in an in Vitro Pharmacokinetic Model.” Journal of Antimicrobial Chemotherapy (JAC) 78 (9): 2254–62. doi:10.1093/jac/dkad230.